Comparison
While Semaglutide is approved for type 2 diabetes and chronic weight management, significantly lowering HbA1c and body weight by modulating incretin pathways232480, Tesamorelin is FDA-approved to reduce excess visceral adipose tissue in HIV-associated lipodystrophy and is studied for broader body-composition, NAFLD, and cognitive effects via GH/IGF-1 axis modulation1893.
While Semaglutide works as a modified GLP-1(7–37) analog with three key changes—Ala8→Aib, Lys26 acylated with a C18 fatty diacid, and Lys34→Arg—resulting in a long-acting GLP-1 receptor agonist that enhances glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and reduces appetite23647480, Tesamorelin is a full-length 44-amino-acid GHRH analog with an N-terminal trans-3-hexenoic acid modification that binds GHRHR, activating cAMP/PKA signaling to increase endogenous GH and IGF-1, with improved stability versus native GHRH182893102.
Semaglutide is 31 amino acids long, whereas Tesamorelin is longer as it has a length of 44 amino acids. Semaglutide is made up of a sequence of sequence data not available in the current dataset. Tesamorelin is made up of a sequence of Tyrosine, Alanine, Aspartic acid, Alanine, Isoleucine, Phenylalanine, Threonine, Asparagine, Serine, Tyrosine, Arginine, Lysine, Valine, Leucine, Glycine, Glutamine, Leucine, Serine, Alanine, Arginine, Lysine, Leucine, Leucine, Glutamine, Aspartic acid, Isoleucine, Methionine, Serine, Arginine, Glutamine, Glutamine, Glycine, Glutamic acid, Serine, Asparagine, Glutamine, Glutamic acid, Arginine, Glycine, Alanine, Arginine, Alanine, Arginine, Leucine.
Semaglutide
GCG
Tesamorelin
GHRH